NCT02426034已完成4 期
Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 2,004
- 试验地点
- 2
- 主要终点
- Safety, which was assessed by recording the incidence and severity of adverse events
研究概览
简要总结
The large-scale phase IV study aims to verify the safety and efficacy of apatinib in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma after failure of two lines of chemotherapy. Apatinib initiated at a recommended dose of 850mg. However, the starting dose was decided by investigator's choice based on patients' condition. Dose interruption and dose reduction were allowed according to the product label. Treatment continued until disease progression, intolerable toxicity, withdrawal of informed consent, or at investigators' discretion. The primary endpoint was safety, which was assessed by recording the incidence and severity of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 to75 years old;
- •Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction);
- •Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens;
- •ECOG PS of 0-2;
- •Major organ function has to meet the following criteria:
- •For results of blood routine test (without blood transfusion within 14 days):
- •HB ≥ 90g / L ANC ≥ 1.5 × 109 / L PLT ≥ 80 × 109 / L
- •Biochemical tests results:
- •Bilirubin <1.25 times the upper limit of normal (ULN) ALT and AST <2.5 × ULN; liver metastases, if any, the ALT and AST<5 × ULN Serum Cr ≤ 1 × ULN endogenous creatinine clearance>50ml/min (Cockcroft-Gault formula)
- •An expected survival of ≥ 3 months;
- •Patient received apatinib treatment regimen at investigators' discretion;
- •Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
- •Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.
排除标准
- •Subjects with uncontrolled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Grade ≥ 2 coronary heart disease; Grade ≥ 2 arrhythmia (including QT interval prolongation, for man > 450 ms, for woman > 470 ms), as well as Grade ≥ 2 cardiac dysfunction;
- •Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
- •Subjects with high gastrointestinal bleeding risk, including the following conditions: presence of active ulceration combined with a positive fecal occult blood test (++);history of hematemesis and melena within three months before enrollment; unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy finding;
- •Abnormal coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleeding;
- •Presence of central nervous system metastases;
- •Pregnant or lactating women;
- •Other conditions regimented at investigators' discretion.
研究组 & 干预措施
Treatment group
Experimental
Apatinib Tablets
干预措施: ApatinibTablets (Drug)
结局指标
主要结局
Safety, which was assessed by recording the incidence and severity of adverse events
时间窗: between first dose of apatinib and up to 30 days after the last dose of apatinib
次要结局
- Disease Control Rate(An expected average of 12 weeks)
- Objective Response Rate(An expected average of 12 weeks)
- Quality of life, measured by the questionnaire of EORTC QLQ-C30(Quality of life will be assessed at baseline (after the patients provided written informed consent) until at least 4 weeks after the last dose of study drug was administered, an expected average of 14 weeks)
- Progression Free Survival(An expected average of 12 weeks)
- Overall Survival(Event driven, an expected average of 34 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Apatinib for Advanced Non-squamous Head and Neck CancerHead and Neck NeoplasmsNCT02989259Cancer Institute and Hospital, Chinese Academy of Medical Sciences30
Unknown
2 期
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast CancerBreast Cancer MetastaticNCT03086785Hebei Medical University Fourth Hospital120
Unknown
2 期
A Study of Apatinib in Recurrent or Recurrent High-grade GliomaGliomaNCT03390062West China Hospital30
Unknown
1 期
Study of Apatinib and MASCT in Patients With Advanced Solid TumorsAdvanced Solid TumorsExcluding T Cell LymphomaNCT02844881The First People's Hospital of Lianyungang60
Unknown
不适用
A Real World Study of Apatinib in Treatment of Patients With Gastric CarcinomaGastric CarcinomaNCT03735511Henan Cancer Hospital270